Logo

Qiagen CGT Viral Vector Lysis Kit, Customized Biopharma dPCR Assay Design Service

Jul 21, 2023

Qiagen has launched a new digital PCR kit and a service to support customers developing cell and gene therapy (CGT) applications. 

The CGT Viral Vector Lysis Kit enables a standardized workflow from cell lysates to perform absolute and precise quantification of viral titers for multiple serotypes using the Qiagen QiAcuity dPCR system.

Qiagen has also partnered with Niba Labs, an analytical laboratory with expertise in dPCR assay development and sample testing, to offer a customized dPCR assay design service for biopharma. The service allows customers using Qiagen's QiAcuity dPCR system to develop new custom simplex or multiplex assays for the quantification of nucleic acids and to optimize existing qPCR assays for the use in digital PCR. Niba Labs will evaluate the performance of the assays and validate them for cell and gene therapy developers.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.